Curtis Dale - Cocrystal Pharma Interim CFO
| COCP Stock | USD 1.50 0.07 4.90% |
CFO
Mr. Curtis Dale is Interim Chief Financial Officer of Cocrystal Pharma, Inc., Since midNovember 2015, Mr. Dale has acted as Interim Chief Financial Officer. He joined Cocrystal in September 2015 and served as Controller of Cocrystal. From April 2014 through March 2015, he served as Director of Financial Planning and Analysis for Carestream Dental LLC. Prior to that, from August 2012 through April 2014, he served as Director of Accounting and Finance for Gabriel Brothers, Inc. From 2011 through August 2012, Mr. Dale was a financial consultant for both NCR and CibaVision. He served as the Chief Financial Officer for MedLink Georgia, Inc. in 2010 and 2011 and from 2008 through 2010, he served as the Executive Director of Finance and Administration for Saint Josephs Translational Research Institute. Mr. Dale served as Executive Finance Director for Stiefel Laboratories, for 2 years, as Corporationrationrate Controller for Solvay Pharmaceuticals for over 9 years, and various financial positions of increasing responsibility with BristolMyers Squibb. since 2015.
| Age | 59 |
| Tenure | 9 years |
| Address | 19805 North Creek Parkway, Bothell, WA, United States, 98011 |
| Phone | 305 425 1780 |
| Web | https://www.cocrystalpharma.com |
Cocrystal Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3668) % which means that it has lost $0.3668 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5454) %, meaning that it created substantial loss on money invested by shareholders. Cocrystal Pharma's management efficiency ratios could be used to measure how well Cocrystal Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/19/2024, Return On Tangible Assets is likely to drop to -0.6. In addition to that, Return On Capital Employed is likely to drop to -0.79. As of 04/19/2024, Non Current Liabilities Other is likely to grow to about 366.4 K, while Total Current Liabilities is likely to drop slightly above 2.7 M.Similar Executives
| Found 9 records | CFO Age | ||
| David Riggs | Eagle Pharmaceuticals | 64 | |
| Pete Meyers | Eagle Pharmaceuticals | 48 | |
| Timothy Coughlin | Neurocrine Biosciences | 48 | |
| Thomas Kelly | Deciphera Pharmaceuticals LLC | 47 | |
| James Frates | Alkermes Plc | 50 | |
| Kelly MacDonald | Dynavax Technologies | 40 | |
| Gina Consylman | Ironwood Pharmaceuticals | 45 | |
| Thomas Graney | Ironwood Pharmaceuticals | 51 | |
| Matt Abernethy | Neurocrine Biosciences | 37 | |
Management Performance
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.37 |
Cocrystal Pharma Leadership Team
Elected by the shareholders, the Cocrystal Pharma's board of directors comprises two types of representatives: Cocrystal Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cocrystal. The board's role is to monitor Cocrystal Pharma's management team and ensure that shareholders' interests are well served. Cocrystal Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cocrystal Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Kornberg, Chairman, CoFounder | ||
| CPA CPA, CFO CoCEO | ||
| Curtis Dale, Interim CFO | ||
| Steven Rubin, Director | ||
| Sam Lee, Co-Founder and Pres | ||
| Raymond Schinazi, Director | ||
| Gary Wilcox, Co-Founder, Vice Chairman, Sr. Advisor and Member of Scientific Review Committee | ||
| James Martin, CFO | ||
| Jeffrey Meckler, CEO and Director | ||
| Anthony Japour, Director | ||
| Phillip Frost, Director | ||
| David Block, Director | ||
| Douglas Mayers, Chief Marketing Officer | ||
| Walt Linscott, Director | ||
| Jane Hsiao, Director | ||
| Todd Brady, Director |
Cocrystal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cocrystal Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | (9.95 M) | ||||
| Shares Outstanding | 10.17 M | ||||
| Shares Owned By Insiders | 30.03 % | ||||
| Shares Owned By Institutions | 6.70 % | ||||
| Number Of Shares Shorted | 4.96 K | ||||
| Price To Earning | 193.33 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 92.45 X |
Pair Trading with Cocrystal Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Cocrystal Stock
| 0.64 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
| 0.6 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
| 0.53 | VERA | Vera Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.47 | VCEL | Vericel Corp Ord Downward Rally | PairCorr |
| 0.46 | VINC | Vincerx Pharma Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.
The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cocrystal Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.Note that the Cocrystal Pharma information on this page should be used as a complementary analysis to other Cocrystal Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Cocrystal Stock analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Cocrystal Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cocrystal Pharma. If investors know Cocrystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cocrystal Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.87) | Revenue Per Share 0.006 | Quarterly Revenue Growth 0.269 | Return On Assets (0.37) | Return On Equity (0.55) |
The market value of Cocrystal Pharma is measured differently than its book value, which is the value of Cocrystal that is recorded on the company's balance sheet. Investors also form their own opinion of Cocrystal Pharma's value that differs from its market value or its book value, called intrinsic value, which is Cocrystal Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cocrystal Pharma's market value can be influenced by many factors that don't directly affect Cocrystal Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cocrystal Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cocrystal Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cocrystal Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.